Macquarie Group Ltd. Trims Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Macquarie Group Ltd. Trims Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Macquarie Group Ltd. decreased its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) by 1.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 58,317 shares of the biotechnology company's stock after selling 581 shares during the period. Macquarie Group Ltd. owned 0.08% of Rocket Pharmaceuticals worth $940,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Rocket Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 3,349,160 shares of the biotechnology company's stock worth $53,118,000 after acquiring an additional 48,022 shares in the last quarter. State Street Corp boosted its holdings in Rocket Pharmaceuticals by 17.5% in the first quarter. State Street Corp now owns 2,753,647 shares of the biotechnology company's stock valued at $43,673,000 after purchasing an additional 410,234 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 133.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,551,774 shares of the biotechnology company's stock valued at $24,612,000 after acquiring an additional 886,919 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Rocket Pharmaceuticals by 102.2% during the third quarter. Dimensional Fund Advisors LP now owns 883,569 shares of the biotechnology company's stock worth $14,099,000 after purchasing an additional 446,574 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Rocket Pharmaceuticals by 1.6% in the second quarter. JPMorgan Chase & Co. now owns 851,594 shares of the biotechnology company's stock valued at $11,718,000 after buying an additional 13,679 shares in the last quarter. 93.23% of the stock is currently owned by institutional investors.
Get Rocket Pharmaceuticals alerts:Analyst Upgrades and Downgrades
RCKT has been the topic of several research analyst reports. SVB Leerink reduced their price objective on Rocket Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research note on Monday, January 23rd. Morgan Stanley initiated coverage on Rocket Pharmaceuticals in a research report on Wednesday, February 1st. They set an "overweight" rating and a $45.00 price objective for the company. Chardan Capital reduced their price target on Rocket Pharmaceuticals from $65.00 to $63.00 and set a "buy" rating for the company in a research report on Wednesday, March 1st. Bank of America cut their target price on Rocket Pharmaceuticals from $38.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, December 23rd. Finally, Needham & Company LLC restated a "buy" rating and issued a $60.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 28th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $52.58.
Rocket Pharmaceuticals Stock Performance
Shares of RCKT opened at $18.46 on Monday. The stock's 50-day simple moving average is $20.28 and its 200 day simple moving average is $18.38. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -5.61 and a beta of 1.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.29 and a current ratio of 9.29. Rocket Pharmaceuticals, Inc. has a 52-week low of $7.57 and a 52-week high of $23.48.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) last issued its quarterly earnings data on Monday, February 27th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.10). During the same period last year, the firm earned ($0.69) earnings per share. Research analysts forecast that Rocket Pharmaceuticals, Inc. will post -3.3 EPS for the current fiscal year.
Insider Buying and Selling at Rocket Pharmaceuticals
In other news, insider Jonathan David Schwartz sold 3,557 shares of the stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $19.06, for a total transaction of $67,796.42. Following the transaction, the insider now directly owns 94,546 shares in the company, valued at approximately $1,802,046.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Gaurav Shah sold 12,194 shares of the business's stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $19.06, for a total value of $232,417.64. Following the sale, the chief executive officer now directly owns 536,885 shares in the company, valued at $10,233,028.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan David Schwartz sold 3,557 shares of the company's stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $19.06, for a total value of $67,796.42. Following the transaction, the insider now directly owns 94,546 shares in the company, valued at approximately $1,802,046.76. The disclosure for this sale can be found here. Insiders own 33.67% of the company's stock.
Rocket Pharmaceuticals Profile
(Get Rating)
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms.
Further Reading
- Get a free copy of the StockNews.com research report on Rocket Pharmaceuticals (RCKT)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding RCKT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating).
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
麦格理集团(Macquarie Group Ltd.)最近提交给美国证券交易委员会的文件显示,该公司在第三季度减持了1%的火箭制药股份。该公司在此期间出售了581股后,持有这家生物技术公司58,317股股票。截至最近一次报告期末,麦格理集团有限公司持有火箭制药0.08%的股份,价值94万美元。
其他机构投资者也调整了对该公司的持股。先锋集团在第一季度增持了1.5%的Rocket PharmPharmticals股份。先锋集团(Vanguard Group Inc.)在上个季度增持了48,022股后,目前持有这家生物技术公司3,349,160股股票,价值53,118,000美元。道富集团第一季度增持了17.5%的Rocket PharmPharmticals股份。道富集团目前持有这家生物技术公司2,753,647股股票,价值43,673,000美元,此前该公司在上个季度又购买了410,234股。高盛股份有限公司在第一季度增持了133.4%的火箭制药股份。高盛股份有限公司在此期间增持了886,919股,目前持有这家生物技术公司1,551,774股股票,价值24,612,000美元。Dimension Fund Advisors LP在第三季度增持了102.2%的Rocket PharmPharmticals股票。Dimension Fund Advisors LP现在拥有这家生物技术公司885,569股票,价值14,099,000美元,在此期间又购买了446,574股票。最后,摩根大通在第二季度将其在Rocket PharmPharmticals股票的持仓增加了1.6%。摩根大通(JPMorgan Chase&Co.)目前持有这家生物技术公司851,594股股票,价值11,718,000美元,上一季度又购买了13,679股。93.23%的股票目前由机构投资者持有。
到达火箭制药公司警报:分析师升级和下调评级
RCKT一直是几份研究分析师报告的主题。SVB Leerink在1月23日(星期一)的一份研究报告中将其对Rocket PharmPharmticals的目标价从50.00美元下调至49.00美元,并对该股设定了“跑赢大盘”的评级。2月1日,星期三,摩根士丹利在一份研究报告中发起了对火箭制药的报道。他们为该公司设定了“增持”评级和45.00美元的目标价。Chardan Capital在3月1日(周三)的一份研究报告中将其对Rocket PharmPharmticals的目标价从65.00美元下调至63.00美元,并为该公司设定了“买入”评级。12月23日周五,美国银行在一份研究报告中将Rocket PharmPharmticals的目标价从38.00美元下调至35.00美元,并对该股设定了“买入”评级。最后,Needham&Company LLC在2月28日(星期二)的一份研究报告中重申了“买入”评级,并发布了火箭制药公司股票的目标价60.00美元。一位分析师对该股的评级为卖出,12位分析师给出了该公司的买入评级。根据MarketBeat.com的数据,该公司的平均评级为“中等买入”,平均目标价为52.58美元。
火箭制药类股表现
周一,RCKT的股价开盘报18.46美元。该股的50日简单移动均线切入位为20.28美元,200日简单移动均线切入位为18.38美元。该股市值14.6亿美元,市盈率为-5.61,贝塔系数为1.23。该公司的债务权益比率为0.04,速动比率为9.29,流动比率为9.29。Rocket PharmPharmticals,Inc.的52周低点为7.57美元,52周高点为23.48美元。
火箭制药(纳斯达克代码:RCKT-GET Rating)最近一次发布季度收益数据是在2月27日星期一。这家生物技术公司公布的季度每股收益(EPS)为0.92美元,低于分析师普遍预期的0.82美元和0.10美元。去年同期,该公司每股收益为0.69美元。研究分析师预测,火箭制药公司本财年每股收益将达到3.3%。
火箭制药公司的内幕买卖
在其他新闻方面,内部人士乔纳森·David·施瓦茨在2月17日星期五的交易中出售了3,557股该公司股票。该股以19.06美元的平均价格出售,总成交金额为67,796.42美元。交易完成后,这位内部人士现在直接持有该公司94,546股股票,价值约1,802,046.76美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。在相关新闻中,首席执行官高拉夫·沙阿在日期为2月17日(星期五)的交易中出售了12,194股该公司股票。这只股票的平均售价为19.06美元,总价值为232,417.64美元。出售后,首席执行官现在直接拥有该公司536,885股,价值10,233,028.10美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。此外,内部人士乔纳森·David·施瓦茨在2月17日星期五的一次交易中出售了3,557股该公司股票。这些股票的平均价格为19.06美元,总价值为67,796.42美元。交易完成后,这位内部人士现在直接持有该公司94,546股股票,价值约1,802,046.76美元。关于这次销售的披露可以找到这里。内部人士持有该公司33.67%的股份。
火箭制药公司简介
(获取评级)
火箭制药公司是一家临床阶段的生物技术公司,致力于为罕见和毁灭性的儿科疾病开发基因疗法治疗方案。其多平台开发方法应用了慢病毒载体和腺相关病毒载体基因治疗平台。
进一步阅读
- 免费获取StockNews.com关于火箭制药的研究报告(RCKT)
- SVB金融崩溃对美国银行意味着什么
- 市场回顾周-3/6/3/10
- 2个近海钻探公司将大赚一笔
- 未来有望实现两位数上涨的三只史泰博股票
- 投资者能信任消费者来提升美国户外品牌吗?
想看看其他对冲基金持有RCKT吗?访问HoldingsChannel.com获取火箭制药公司(纳斯达克代码:RCKT-GET Rating)的最新13F备案文件和内幕交易信息。
接受《火箭药业日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Rocket PharmPharmticals和相关公司的最新新闻和分析师评级的每日摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧